Related Experiment Videos
Chalk and cheese: symptomatic hypocalcaemia during paediatric anti-tuberculous therapy
David Burgner1, Elisabeth Schölvinck, Michael Coren
1School of Paediatrics and Child Health, University of Western Australia, Princess Margaret Medical Centre, WA, Australia. dburgner@paed.uwa.edu.au
Insights
Standard anti-tuberculosis drugs can disrupt vitamin D and calcium levels in children. This case study highlights hypocalcaemia in two pediatric patients due to these therapies, emphasizing the need for monitoring.
Area of Science:
- Pediatric Endocrinology
- Pharmacology
- Infectious Diseases
Background:
- Standard anti-tuberculosis therapy is crucial for treating Mycobacterium tuberculosis infections.
- Vitamin D metabolism and calcium homeostasis are vital for overall health.
- Disruption of these metabolic pathways can lead to significant health issues.
Observation:
- Two pediatric patients undergoing anti-tuberculosis treatment presented with symptomatic hypocalcaemia.
- The hypocalcaemia was found to be secondary to hypovitaminosis D.
- Rifampicin and isoniazid were identified as the likely precipitating agents.
Findings:
- Anti-tuberculosis drugs, specifically rifampicin and isoniazid, can adversely affect vitamin D metabolism in children.
- This disruption can lead to clinically significant hypocalcaemia.
- This interaction is previously unreported in the pediatric population.
Implications:
- Clinicians should be aware of the potential for vitamin D and calcium disturbances in children treated for tuberculosis.
- Monitoring of vitamin D and calcium levels may be warranted during anti-tuberculosis therapy.
- Further research is needed to elucidate the mechanisms and prevalence of this interaction.
Abstract:
Standard anti-tuberculosis therapy may disrupt normal vitamin D metabolism and consequently calcium homeostasis, but this is previously unreported in paediatric patients. We describe two children developed symptomatic hypocalcaemia secondary to hypovitaminosis D, which had been precipitated by rifampicin and isoniazid. The complex relationship between tuberculosis, anti-tuberculosis therapy, vitamin D metabolism and calcium, together with the clinical implications, are discussed.
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...